Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction (INSIGHT-STEMI)
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This study is a prospective, multicenter, randomized controlled, superiority clinical trial. Eligible subjects who meet the inclusion/exclusion criteria will be randomly assigned in a 1:1 ratio to either the IVUS-guided strategy (experimental group) or the conventional coronary angiography-guided strategy (control group). The study plans to enroll at least 2488 subjects, with 1244 subjects in each of the experimental and control groups. Zhongshan Hospital, Fudan University serves as the lead center. A competitive enrollment approach will be adopted, with the number of cases enrolled by the lead center not exceeding 50% of the total sample size.
In the IVUS group, intravascular ultrasound (IVUS) will be used for guidance; the use of high-frequency intravascular ultrasound (resolution ≥ 50 MHz) is encouraged, though not mandatory.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Chenguang Li, Doctor
- Telefonnummer: +8613816767665
- E-mail: li.chenguang@zs-hospital.sh.cn
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Zhongshan hospital
-
Ledende efterforsker:
- Junbo Ge, Doctor
-
Kontakt:
- Chenguang Li, Doctor
- Telefonnummer: +8613816767665
- E-mail: li.chenguang@zs-hospital.sh.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion criteria
- Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;
- Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);
- Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;
- The IVUS catheter is expected to pass through the target lesion to complete the examination.
Exclusion Criteria
- Patients with cardiogenic shock or severe heart failure (Killip class IV);
- Patients who have previously undergone coronary artery bypass grafting (CABG);
- Patients with coma or disturbance of consciousness;
- Patients who are expected to be intolerant to long-term antiplatelet therapy;
- Pregnant women;
- Life expectancy < 1 year;
- Currently participating in another drug/device clinical trial and not having reached the primary endpoint;
- Poor compliance, expected to be unable to complete follow-up.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: IVUS group
In the experimental group, after the guidewire passes through the lesion, IVUS is used to guide the primary PCI procedure.
|
a catheter equipped with an ultrasound transducer is advanced over a guidewire into the vessel lumen distal to the target coronary lesion.
Then, while slowly withdrawing the catheter, 360-degree cross-sectional images of the vessel are acquired to accurately measure lumen dimensions, assess plaque characteristics, select an appropriately sized stent, and confirm that after stent implantation the stent is fully apposed, well expanded, and free of vascular complications.
Andre navne:
|
|
Andet: CAG group
In the control group, after the guidewire passes through the lesion, coronary angiography is used to guide the primary PCI procedure
|
A catheter is inserted through a peripheral artery (e.g., femoral or radial artery) and advanced to the ostium of the coronary arteries under fluoroscopic guidance.
Once positioned, contrast medium is injected while X-ray images are acquired to visualize the coronary artery lumen and detect any stenoses or occlusions.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary target vessel failure (TVF) rate
Tidsramme: 1 year
|
defined as the composite endpoint of cardiac death, ischemia-driven target vessel revascularization, and target vessel-related myocardial infarction.
|
1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Lesion success rate
Tidsramme: Perioperative
|
Lesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
|
Perioperative
|
|
Clinical success rate
Tidsramme: Pre-discharge
|
Lesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
|
Pre-discharge
|
|
Mortality rate
Tidsramme: 1 Year
|
Includes cardiovascular death, non-cardiovascular death, and death of undetermined cause
|
1 Year
|
|
Incidence of myocardial infarction
Tidsramme: 1 year
|
includes periprocedural myocardial infarction as defined by SCAI and spontaneous myocardial infarction (infarct-related artery-related vs. non-infarct-related artery-related; culprit lesion-related vs. non-culprit lesion-related)
|
1 year
|
|
Revascularization
Tidsramme: 1 year
|
includes ischemia-driven and non-ischemia-driven revascularization, revascularization of infarct-related and non-infarct-related arteries, revascularization of culprit and non-culprit lesions, revascularization of target vessels and non-target vessels, and revascularization of target lesions and non-target lesions
|
1 year
|
|
Stent thrombosis
Tidsramme: 1 year
|
Academic Research Consortium
|
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Junbo Ge, Doctor, Fudan University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Hjertesygdomme
- Infarkt
- Nekrose
- Myokardieiskæmi
- Myokardieinfarkt
- Iskæmi
- Patologiske tilstande, tegn og symptomer
- ST Elevation Myokardieinfarkt
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Minimalt invasive kirurgiske procedurer
- Diagnostisk billeddannelse
- Ultrasonografi
- Interventionel ultralydsskanning
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- B2025-555
- ChiCTR2600124260 (Anden identifikator: Chinese Clinical Trail Registry)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .